CorMedix/$CRMD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About CorMedix
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
- Ticker
- $CRMD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 191
- Headquarters
- Parsippany, United States
- Website
- cormedix.com
CorMedix Metrics
BasicAdvanced
$413M
2.54
$2.08
1.50
-
Price and volume
Market cap
$413M
Beta
1.5
52-week high
$13.02
52-week low
$5.10
Average daily volume
1.6M
Financial strength
Current ratio
2.564
Quick ratio
2.231
Long term debt to equity
0.32
Total debt to equity
0.32
Interest coverage (TTM)
81.68%
Profitability
EBITDA (TTM)
262.548
Gross margin (TTM)
90.21%
Net profit margin (TTM)
40.49%
Operating margin (TTM)
49.16%
Effective tax rate (TTM)
7.98%
Revenue per employee (TTM)
$2,420,000
Management effectiveness
Return on assets (TTM)
24.56%
Return on equity (TTM)
54.93%
Valuation
Price to earnings (TTM)
2.544
Price to revenue (TTM)
0.897
Price to book
0.89
Price to tangible book (TTM)
5.69
Price to free cash flow (TTM)
1.655
Free cash flow yield (TTM)
60.41%
Free cash flow per share (TTM)
3.202
Growth
Revenue change (TTM)
280.50%
Earnings per share change (TTM)
163.53%
3-year revenue growth (CAGR)
2,230.52%
10-year revenue growth (CAGR)
128.95%
3-year earnings per share growth (CAGR)
34.53%
10-year earnings per share growth (CAGR)
-1.75%
What the Analysts think about CorMedix
Analyst ratings (Buy, Hold, Sell) for CorMedix stock.
Analyst projections of the future price of CorMedix stock.
Bulls say / Bears say
CorMedix is generating meaningful profits and cash: Q2 2026 adjusted EBITDA was $58.7 million, and management raised its full-year adjusted EBITDA guidance to $125–140 million. It reported $256.7 million in cash and short-term investments at quarter-end. (CorMedix)
DefenCath has contracts with all five of the largest US dialysis providers, widening its route to patients. Q2 sales were $66.1 million, with utilisation by large outpatient customers supporting demand; the newest provider has begun ordering and plans a pilot. (CorMedix)
REZZAYO’s Phase III prophylaxis trial met its primary endpoint, and CorMedix expects an application for the expanded use in 2026. If approved, the new indication could add a growth opportunity from 2027. (CorMedix)
DefenCath has moved from separate transitional reimbursement to a bundled payment, making revenue and margins more sensitive to reimbursement rates. Management said it discounted pricing to help preserve patient volumes, while the 2027 add-on calculation will vary by quarter. (Investing.com, CorMedix)
Near-term DefenCath volume growth is not assured: the newest large dialysis provider is starting with a pilot, while management said meaningful growth depends on adoption there or on securing Medicare Advantage contracts. Management also reported attrition among smaller providers after the reimbursement transition. (The Motley Fool)
The Phase III study of DefenCath in total parenteral nutrition patients has faced slow enrolment, and completion is now expected in 2028. That delays a potential expansion into another patient market and leaves the programme exposed to further trial execution risk. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2026.
CorMedix Financial Performance
Revenues and expenses
CorMedix Earnings Performance
Company profitability
Upcoming events
No upcoming events
CorMedix News
AllArticlesVideos
Funds containing CorMedix
Fund name | Fund size | $CRMD weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.03% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.01% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $2.7B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.